NCT01497652View on ClinicalTrials.gov

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Parkinson's Disease
Interventions
DRUG

Rasagiline/Placebo

Will receive placebo pills each day for the entire 14 weeks.

DRUG

Rasagiline

0.5 mg for two weeks, then 1 mg for 12 weeks.

Trial Locations (1)

20007

Georgetown University Hospital, Washington D.C.

All Listed Sponsors
collaborator

Teva Neuroscience, Inc.

INDUSTRY

lead

Georgetown University

OTHER

NCT01497652 - A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy | Biotech Hunter | Biotech Hunter